In this episode recorded live at A4M Longevity Fest, hosts Tom Blue and Chris D'Adamo interview Ryan Smith, Founder and Global Head of R&D at TruDiagnostic. The discussion highlights the meteoric rise of biological age testing, which has seen a 140% year-over-year increase in consumer interest. Smith details how TruDiagnostic is evolving beyond simple aging clocks to becoming a comprehensive healthcare platform, introducing new "methylation risk scores" for chronic diseases and "epigenetic biomarker proxies" that aim to eventually replace traditional phlebotomy labs like Quest and Labcorp.

Key Discussion Points

• The "Why" Behind the Boom: The convergence of mature science (epigenetic clocks), the recognition of aging as the primary driver of chronic disease, and massive capital investment ($9 billion) has propelled the industry forward.

• Epigenetics vs. Genomics: Unlike genomics, which provides a static assessment of risk (what you are born with), epigenetics measures gene expression that is dynamic and modifiable, allowing patients to track the effectiveness of their interventions.

• Rejuvenation Olympics: TruDiagnostic acts as the "scorekeeper" for a global competition involving over 15,000 participants striving for the best reduction in biological age.

• Methylation Risk Scores: In February, the company is launching 35 new risk scores for conditions like COPD and Diabetes, predicting disease onset 5 to 10 years in advance.

• Epigenetic Biomarker Proxies (EBPs): The lab can now derive over 2,000 traditional blood markers (like HbA1c, CRP, and Omega-3s) solely from the epigenetic data in a single blood spot, potentially eliminating the need for cold-chain shipping and large blood draws.

• New Diagnostic Codes: TruDiagnostic has secured 12 PLA codes from the AMA, allowing for insurance-reimbursable diagnoses of specific conditions such as Lyme disease and Hepatocellular Carcinoma.

Actionable Insights for Practitioners

• Gamify Patient Health: Utilize the concept of "longevity as a sport" to keep patients engaged; tracking biological age reduction can serve as a primary outcome metric for your practice's interventions.

• Look for Reimbursable Options: While preventive risk scores generally remain cash-pay, practitioners can soon order specific epigenetic diagnostic tests (e.g., for Liver Cancer or Lyme) that are eligible for insurance reimbursement.

• Utilize Proxies for Root Cause Analysis: When a patient shows a high disease risk score (e.g., for Alzheimer's), use Epigenetic Biomarker Proxies to determine the specific driver, such as insulin resistance or inflammation, to tailor the treatment plan.

• Prepare for "No Phlebotomy": As the technology matures, consider how shifting to finger-stick epigenetic tests can streamline your operations by replacing the need for phlebotomists and refrigerated shipping for standard biomarkers.

Featured Resources & Calls to Action

• Lab & Education: TruDiagnostic – For testing kits and research information.

• Community: Rejuvenation Olympics – The leaderboard and competition for biological age reduction.

• Resource: Visit the Innovations in Clinical Implementation landing page for exclusive resources.

Analogies for Understanding

"Scorekeeping": Tom Blue compares the measurement of biological aging to "scorekeeping" in the sport of longevity. Just as athletes need a scoreboard to know if they are winning, patients need biological age testing to know if their health interventions are actually working.